Fear Conditioning during specific conditions in Antisocial Adolescents: A Neuroimaging Study.
Recruiting
- Conditions
- Disrupted Behavior Disorder (DBD)Oppositional Defiant Disorder (ODD)Conduct Disorder (CD)
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 83
Inclusion Criteria
DBD:
- Male
Exclusion Criteria
DBD:
- Standard exclusion criteria (NIH) for MRI are the presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Differental BOLD-response in the fear conditioning brain network during fear conditioning and during reward/punishment sensitivity.
- Secondary Outcome Measures
Name Time Method Fear conditioning level (CS+ vs CS- differentiation in skin conductance level, pupil dilatation, self-reported arousal and emotional valence). <br /><br>-Reward/punishment sensitivity (reaction time). <br /><br>-Risk taking behavior (number of pumps in risk taking behavior task). <br /><br>-Connectivity between brain structures through Diffusion Tensor Imaging (DTI) techniques and resting-state fMRI <br /><br>- brain structure through structural MRI.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What neural circuits are implicated in fear conditioning deficits in Conduct Disorder as studied in NL-OMON21639?
How does fear conditioning neuroimaging in NL-OMON21639 compare to standard behavioral therapies for Oppositional Defiant Disorder?
Which neuroimaging biomarkers in Disrupted Behavior Disorder predict response to fear conditioning-based behavioral interventions?
What psychological adverse events are associated with fear conditioning protocols in adolescents with Conduct Disorder?
Are there pharmacological agents targeting amygdala dysfunction in Conduct Disorder that could complement NL-OMON21639 findings?